CoChat

Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin

Fang, Jun, Sawa, Tomohiro, Akaike, Takaaki, Greish, Khaled, Maeda, Hiroshi · 2004 · International Journal of Cancer
Cited by 156

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Heme oxygenase‐1 (HO‐1), an inducible enzyme that catalyzes oxidative degradation of heme to form biliverdin, carbon monoxide and free iron, may protect tumor cells against oxidative stress, thus contributing to rapid tumor growth in vivo. Here, we discuss whether pegylated zinc protoporphyrin (PEG‐ZnPP), a potent HO inhibitor, modulates the chemotherapeutic response of tumor cells to treatment that generates reactive oxygen species (ROS). PEG‐ZnPP is a water‐soluble HO inhibitor that accumulates in tumor tissues after intravenous administration. Cytotoxicity of antitumor agents in vitro was determined by means of MTT and annexin V assays using human colon carcinoma SW480 cells. Mice bearing sarcoma 180 tumors were used as an in vivo model. Pegylated D‐amino acid oxidase (PEG‐DAO), which behaves as an oxidative chemotherapeutic agent by generating toxic oxidants at tumor tissues, was administered with its substrate D‐proline to mice with or without PEG‐ZnPP pretreatment. PEG‐ZnPP‐treated SW480 cells became vulnerable to insults caused by various cytotoxic agents; the 50% lethal doses were reduced by 25%, 39%, 83%, and 61% for hydrogen peroxide, t‐butyl hydroperoxide, camptothecin and doxorubicin, respectively. Cells treated with PEG‐ZnPP plus cytotoxic oxidants exhibited marked production of intracellular ROS, which paralleled the incidence of apoptosis. PEG‐ZnPP pretreatment significantly reduced tumor growth in mice receiving PEG‐DAO/D‐proline compared to no PEG‐ZnPP pretreatment. These findings suggest that HO‐1 may become an attractive target for chemotherapeutic intervention. Further study of the effect of PEG‐ZnPP plus conventional anticancer drugs that generate ROS, such as cisplatin, camptothecin, doxorubicin, mitomycin C and etoposide, is warranted. © 2003 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.11644

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 156

Metadata

Authors
Fang, J., Sawa, T., Akaike, T., Greish, K., & Maeda, H.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2003-12-04
Volume
109
Issue
1
Pages
1-8
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W2024416107
Cited by
156
References
6
FWCI
2.57
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin. https://app.cochat.ai/papers/10.1002/ijc.11644
The paper
Fang, J., Sawa, T., Akaike, T., Greish, K., & Maeda, H. (2004). Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin. International Journal of Cancer. https://doi.org/10.1002/ijc.11644

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.